Literature DB >> 26398882

MicroRNAs involved with hepatocellular carcinoma (Review).

Bijing Mao1, Ge Wang1.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies, which accounts for 90% of primary liver cancer. HCC usually presents with poor outcomes due to the high rates of tumor recurrence and widespread metastasis. However, the underlying mechanism of HCC initiation and progression, which significantly hindered the development of valid approaches for early detection and treatment remain to be elucidated. As a group of small non-coding RNAs, microRNAs (miRNAs) have been demonstrated to be involved in many types of diseases especially human malignancies. Numerous miRNAs are deregulated in HCC, which may shed some light on current investigations. Since miRNAs are stable and detected easily, their ectopic expression has been reported in HCC tissues, serum/plasma and cell lines. As previously described, miRNAs serve as tumor suppressors or oncogenes, indicating that miRNAs may be useful as diagnostic, therapeutic and prognostic markers of HCC. In the present review, we assessed the latest data regarding dysregulated miRNAs in HCC and reviewed the reported functions of these miRNAs as they apply to the diagnosis and prognosis of HCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26398882     DOI: 10.3892/or.2015.4275

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  29 in total

Review 1.  The role of microRNA in the resistance to treatment of hepatocellular carcinoma.

Authors:  Muhammad Yogi Pratama; Devis Pascut; Muhammad Nasrum Massi; Claudio Tiribelli
Journal:  Ann Transl Med       Date:  2019-10

2.  MiR-874 inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma by targeting SOX12.

Authors:  Tao Jiang; Lian-Yue Guan; Yan-Shuo Ye; Hong-Yu Liu; Rui Li
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

3.  miR-615-5p prevents proliferation and migration through negatively regulating serine hydromethyltransferase 2 (SHMT2) in hepatocellular carcinoma.

Authors:  Xiaoyu Wu; Liang Deng; Decai Tang; Gang Ying; Xuequan Yao; Fukun Liu; Gui Liang
Journal:  Tumour Biol       Date:  2015-12-10

4.  miR-449a inhibits proliferation and invasion by regulating ADAM10 in hepatocellular carcinoma.

Authors:  Songyang Liu; Kai Liu; Wei Zhang; Yingchao Wang; Zhe Jin; Baoxing Jia; Yahui Liu
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

5.  Circ_0091579 Serves as a Tumor-Promoting Factor in Hepatocellular Carcinoma Through miR-1225-5p/PLCB1 Axis.

Authors:  Di Zhang; Yu Zhang; Xiwu Zhang; Hongjun Zhai; Xiaoli Sun; Yiming Li
Journal:  Dig Dis Sci       Date:  2021-02-08       Impact factor: 3.199

6.  miR-3677-5p promotes the proliferation, migration and invasion of hepatocellular carcinoma cells and is associated with prognosis.

Authors:  Hai-Xiang Mao; Bai-Wen Chen; Jie Wang; Chen-Yang Ma; Yi-Chao Gan; Kai-Jie Qiu
Journal:  Exp Ther Med       Date:  2021-05-19       Impact factor: 2.447

7.  Intratumoral γδ T-Cell Infiltrates, Chemokine (C-C Motif) Ligand 4/Chemokine (C-C Motif) Ligand 5 Protein Expression and Survival in Patients With Hepatocellular Carcinoma.

Authors:  Na Zhao; Hien Dang; Lichun Ma; Sean P Martin; Marshonna Forgues; Kris Ylaya; Stephen M Hewitt; Xin Wei Wang
Journal:  Hepatology       Date:  2021-03       Impact factor: 17.298

8.  CXCL5/NF-κB Pathway as a Therapeutic Target in Hepatocellular Carcinoma Treatment.

Authors:  Xingqing Jia; Shuangqin Wei; Wujun Xiong
Journal:  J Oncol       Date:  2021-05-31       Impact factor: 4.375

9.  Clinicopathological role of miR-30a-5p in hepatocellular carcinoma tissues and prediction of its function with bioinformatics analysis.

Authors:  Wen-Ting Huang; Zu-Xuan Chen; Rong-Quan He; Yu-Zhuang Wu; Shu-Ya Yin; Xiao-Na Liang; Gang Chen; Hong Yang; Zhi-Gang Peng; Li-Hua Yang
Journal:  Onco Targets Ther       Date:  2016-08-12       Impact factor: 4.147

10.  miR-138 suppresses cell proliferation and invasion by inhibiting SOX9 in hepatocellular carcinoma.

Authors:  Yahui Liu; Wei Zhang; Kai Liu; Songyang Liu; Bai Ji; Yingchao Wang
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.